Shots:

• The CE Mark approval is based on TRILUMINATE study with positive six-month data assessing edge-to-edge repair technique using TriClip and resulted in reduced severity of TR with improvement in functional capacity- Published in Lancet 2019
• The TriClip device is based on the successful usage of Abbott's MitraClip device which is novel transcatheter mitral valve therapy with 16+ yrs. of safety- survival and durable clinical outcomes in treating people with leaky mitral valves- or MR
• The TriClip is the first minimally invasive clip-based tricuspid valve repair device to avoid open heart surgery- delivered through the femoral vein in the leg and works with clipping leaflets of tricuspid valve with reduction in backflow of blood further enabling easy blood flow and relieving symptoms of TR. Additionally- the TriClip device is available in two different sizes (NT and XT)

Click here ­to­ read full press release/ article

 | Ref: Abbott | Image: Abbott